Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sino Biopharmaceutical ( (HK:1177) ) has provided an update.
Sino Biopharmaceutical announced that its anlotinib hydrochloride capsules, combined with chemotherapy, have been approved by the National Medical Products Administration of China for first-line treatment of advanced or metastatic soft tissue sarcoma. This approval marks a significant milestone as it is the first combination therapy officially approved for this indication worldwide, showcasing the drug’s potential to improve treatment outcomes in a challenging cancer type. The approval is expected to enhance the company’s market positioning and provide new treatment options for patients, addressing unmet clinical needs in the field of soft tissue sarcoma.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited operates in the pharmaceutical industry, focusing on the development and marketing of innovative drugs. The company offers a range of products, including treatments for various cancers such as non-small cell lung cancer, thyroid cancer, and renal cell carcinoma.
YTD Price Performance: 66.88%
Average Trading Volume: 135,230,551
Technical Sentiment Signal: Buy
Current Market Cap: HK$94.79B
For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.